WO1994002132A1 - Traitement de maladies de la peau - Google Patents

Traitement de maladies de la peau Download PDF

Info

Publication number
WO1994002132A1
WO1994002132A1 PCT/AU1993/000354 AU9300354W WO9402132A1 WO 1994002132 A1 WO1994002132 A1 WO 1994002132A1 AU 9300354 W AU9300354 W AU 9300354W WO 9402132 A1 WO9402132 A1 WO 9402132A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
zinc glycerolate
zinc
application
eczema
Prior art date
Application number
PCT/AU1993/000354
Other languages
English (en)
Inventor
Reginald Morton Taylor
Original Assignee
Glyzinc Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glyzinc Pharmaceuticals Limited filed Critical Glyzinc Pharmaceuticals Limited
Priority to AU45486/93A priority Critical patent/AU4548693A/en
Publication of WO1994002132A1 publication Critical patent/WO1994002132A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Definitions

  • This invention relates to a zinc glycerol complex when used for the treatment of particular skin diseases of the human or animal body .
  • the compound of zinc with glycerol is Zinc (1,2,3 - Propanetriolato [2-] - 0*1 , O2) homopolymer, stereoisomer and may be termed zinc monoglycerolate, glycerato-zinc, zinc glycerolate and by its trade mark "Glyzinc".
  • the term zinc glycerolate will be used in this specification.
  • the compound is described for instance in P.C.T. International Publication WO82/01867 in the names of Taylor and Brock, and comprises a specific product of a reaction between certain zinc compounds and glycerol at certain temperature ranges.
  • the compound is described as having uses in the therapeutic or prophylactic treatment of certain disorders of the human or animal skin. It is suggested that the compound may have cosmetic uses and is suggested for the compounding of shaving cream and as a topical application for the prevention of sunburn.
  • P.C.T. International Application WO87/01281 in the name of the present applicant, which unlike the first referred to P.C.T. application refers to the use of the zinc glycerolate as a per oral treatment for gastric bleeding or ulceration or in a topical application as a depot for the slow release of the compound and refers to diffusion through the skin for the treatment of arthritis and zinc insufficiency and includes psoriasis, and refers also to tests against various organisms including fungi, but does not suggest effects in the diseases set out in this specification nor does it suggest prophylactic treatments which it has now been found to have.
  • the skin diseases to which the present invention is directed are acne and eczema.
  • Common acne or more particularly Acne Vulgaris is the most common of skin conditions. It affects the face, shoulders, back and chest.
  • Acne is caused by the blocking of the channel through which sebum liberated from the sebacious gland passes to the skin surface. This blocking results in an inflammatory condition of the underlying sebacious glands.
  • Other forms of acne such as Acne Rosacea may also be treated with this invention.
  • Eczema is a form of inflammation of the skin which passes through several stages. Initially there is redness due to skin blood vessels dilating. Fluid accumulates in the skin causing swelling, itching and blistering. These may burst and become infected but eventually dry scabs and crusts may form.
  • the invention is said to reside in a method of treatment of a human or animal body comprising the step of application of a pharmaceutically acceptable amount by oral, parenteral or topical application of zinc glycerolate for the treatment of skin diseases comprising acne and eczema for prophylactic or therapeutic treatment.
  • the invention is said to reside in the use of zinc glycerolate in a pharmaceutically acceptable amount by oral, parenteral or topical application for the for prophylactic or therapeutic treatment of skin diseases comprising acne and eczema as discussed above .
  • the invention can be said to reside in zinc glycerolate when used as a pharmaceutical in a pharmaceutically acceptable amount by oral, parenteral or topical application the treatment of skin diseases comprising acne and eczema as discussed above for prophylactic or therapeutic treatment.
  • Application of zinc glycerolate can be topical and can be applied as a dry powder or as a suspension in a suitable liquid medium such as a cream or semi-solid medium such as an ointment and can be applied topically by an applicator, for instance by transdermal delivery patch where internal mobilisation in the blood is required for transport to other internal remote areas or application can be by or a spray or puffer pack.
  • a suitable liquid medium such as a cream or semi-solid medium such as an ointment
  • parenteral means such as by injection in a suitable suspension or solution.
  • Oral intake in the form of a tablet, capsule or lozenge may also be suitable for some applications of the invention.
  • One suitable way of treatment might include application as a cream or ointment including in its formulation zinc glycerolate to the affected body part.
  • the application of the zinc glycerolate has a beneficial effect in alleviating the symptoms of or treating a number of diseases.
  • the applicant's have carried out tests to determine the effectiveness of the glycerolate therapy on the conditions and diseases enumerated herein and believe that the results achieved in showing the effectiveness of the compound for treatment of these are entirely unsuspected.
  • Zinc monoglycerolate in the form of a cream was applied to Acne Rosacea and found to have an anti-inflammatory effect superior to hydrocortisone. It was found possible to use the cream including zinc glycerolate as a base under cosmetic make up.
  • a double blind placebo controlled evaluation of the efficacy and safety of zinc glycerolate in the form of a powder in the treatment of mild to moderate childhood atopic eczema was carried out.
  • the placebo was BP Talc.
  • Zinc Glycerolate worked very well in the study as it showed improvements in Global Impression Scores, Global Change Scores, Area affected Mean Score, Total Symptoms Score and Total Eczema Score, these improvements being statistically significant each week over the four weeks of the trial. 2.
  • the Global Change Score for Zinc Glycerolate was 86% improved at four weeks which was higher than the 65% assumed at the time of preparing the trial protocol.
  • Zinc Glycerolate was assessed favourably relative to the placebo by the patients in their diaries. It is concluded that Zinc Glycerolate performed better than expected in the trial.
  • Zinc glycerolate in the form of a powder was applied twice daily to one limb (in all cases the right leg).
  • the powder was well tolerated by all the children with no adverse effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de traitement préventif ou curatif applicable à l'homme ou à des animaux, qui consiste à appliquer par voie orale, parentérale ou topique une quantité acceptable sur le plan pharmaceutique de glycérolate de zinc, pour le traitement de maladies de la peau telles que l'acné ou l'eczéma. L'application de glycérolate de zinc peut se faire sous forme de poudre sèche, de crème ou d'onguent, ou se faire localement à l'aide d'un applicateur.
PCT/AU1993/000354 1992-07-17 1993-07-15 Traitement de maladies de la peau WO1994002132A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45486/93A AU4548693A (en) 1992-07-17 1993-07-15 Treatment of skin diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL3568 1992-07-17
AUPL356892 1992-07-17

Publications (1)

Publication Number Publication Date
WO1994002132A1 true WO1994002132A1 (fr) 1994-02-03

Family

ID=3776296

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/AU1993/000355 WO1994002133A1 (fr) 1992-07-17 1993-07-15 Traitement de brulures
PCT/AU1993/000354 WO1994002132A1 (fr) 1992-07-17 1993-07-15 Traitement de maladies de la peau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/AU1993/000355 WO1994002133A1 (fr) 1992-07-17 1993-07-15 Traitement de brulures

Country Status (1)

Country Link
WO (2) WO1994002133A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028884A1 (fr) * 1993-06-15 1994-12-22 Glyzinc Pharmaceuticals Limited Complexe de monoglycerolate de zinc destine a un traitement anti-rejet du corps humain ou animal
ES2137125A1 (es) * 1997-11-18 1999-12-01 Vinyals S A Lab Dr La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
WO2004005300A1 (fr) * 2002-07-09 2004-01-15 Pure Pharmaceuticals, Inc. Complexes de zinc-glycerol microfins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001867A1 (fr) * 1980-11-24 1982-06-10 Alan J Brock Compose pharmaceutique et procede
AU6286586A (en) * 1985-08-27 1987-03-24 Glyzinc Pharmaceuticals Limited Method of deposition into a human/animal body of a zinc glycerolate complex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001867A1 (fr) * 1980-11-24 1982-06-10 Alan J Brock Compose pharmaceutique et procede
AU6286586A (en) * 1985-08-27 1987-03-24 Glyzinc Pharmaceuticals Limited Method of deposition into a human/animal body of a zinc glycerolate complex

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028884A1 (fr) * 1993-06-15 1994-12-22 Glyzinc Pharmaceuticals Limited Complexe de monoglycerolate de zinc destine a un traitement anti-rejet du corps humain ou animal
ES2137125A1 (es) * 1997-11-18 1999-12-01 Vinyals S A Lab Dr La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
WO2004005300A1 (fr) * 2002-07-09 2004-01-15 Pure Pharmaceuticals, Inc. Complexes de zinc-glycerol microfins

Also Published As

Publication number Publication date
WO1994002133A1 (fr) 1994-02-03

Similar Documents

Publication Publication Date Title
US6667045B2 (en) Topical applications for skin treatment
US6096326A (en) Skin care compositions and use
CN108853312A (zh) 聚桂醇外用凝胶及其制备方法
JPS60100517A (ja) 放射線潰瘍治療剤および方法
US8846646B2 (en) Topical treatment of skin infection
GB1594314A (en) Medicine for the treatment of acne
US20030194446A1 (en) Zinc oxide compositions for dermatheraputics
EP0988040B1 (fr) Utilisation de glucosamine et de derives de glucosamine pour le soulagement rapide de prurit ou de douleurs localisees
JP4243353B2 (ja) 皮膚疾患の治療に用いる共役リノール酸の亜鉛塩
US8513225B2 (en) Composition and method for topical treatment of skin lesions
US4395420A (en) Method and composition for treating pruritis
Happle et al. Systemic retinoid therapy of systematized verrucous epidermal nevus
US5036100A (en) Pharmaceutical method and preparation containing indomethacin
PL190755B1 (pl) Preparat do leczenia i profilaktyki chorób skóry
JPH0436238A (ja) 尋常性▲ざ▼瘡用皮膚外用剤
WO1994002132A1 (fr) Traitement de maladies de la peau
JP2005139210A (ja) 乾癬治療
US5128375A (en) Keloid treating agent
EP2928460A1 (fr) Procédés pour la prévention et le traitement d'affections cutanées inflammatoires
CN112843113A (zh) 一种用于治疗接触性皮炎的制剂
JPH0259519A (ja) 皮膚炎症治療剤
WO1983000628A1 (fr) Procede de traitement de l'acne vulgaire et composition contenant du peroxyde de carbamide
WO1994002131A1 (fr) Traitement de maladies herpetiques
WO2006119540A1 (fr) Preparation destinee a traiter le psoriasis
GR1009073B (el) Εκχυλισματα δεντρολιβανου (rosmarinus officinalis l.) και φασκομηλου (salvia officinalis l. και salvia triloba l.), πλουσια σε διτερπενικες φαινολες, σε παθησεις του δερματος: συνθεσεις και μεθοδοι αντιμετωπισης

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA